trending Market Intelligence /marketintelligence/en/news-insights/trending/bW90VTskgX08eZkkgda5Yw2 content esgSubNav
In This List

Kubota Pharmaceutical to terminate SEC filing obligations

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Kubota Pharmaceutical to terminate SEC filing obligations

Kubota Pharmaceutical Holdings Co., Ltd. plans to terminate its reporting obligations with the U.S. Securities and Exchange Commission.

The Tokyo-based clinical stage ophthalmology company plans to file a Form 15F with the SEC and the obligations will be suspended 90 days after that.

The administrative burden and costs associated with being a U.S. reporting company outweigh the benefits, the company said a news release.

Kubota will continue to its filings with Japanese securities regulators and its common shares will continue to trade on the Tokyo Stock Exchange.